Why did the 1875.HK stock rise today?

The stock jumped on heavy volume after renewed investor interest in BioDlink's oncology pipeline and sector momentum. Media feeds and peer comparisons increased trading. Short-term technical buying also played a role.

What valuation metrics should investors check for 1875.HK?

Key metrics: trailing PE about **261.50**, PB roughly **5.33**, price-to-sales **4.49**, current ratio **2.05**, and EPS **HK$0.02**. These show a high growth premium against clinical-stage cash burn risk.

What is Meyka AI's forecast for 1875.HK stock?

Meyka AI's forecast model projects a 5-year price of **HK$6.45**, versus the current **HK$5.23**, implying **+23.21%** upside. Forecasts are model-based projections and not guarantees.

What catalysts could move BioDlink's stock next?

Positive clinical readouts for TAB008 or TA-series drugs, licence deals, or signs of commercial progress could lift the stock. Negative trial data or dilutive capital raises would be downside catalysts.

HK Stocks

1875.HK BioDlink +16.48% to HK$5.23 on 20 Mar 2026 market closed: outlook

ByDanny Kontos March 20, 2026March 20, 2026

BioDlink International (1875.HK) led Hong Kong healthcare gainers after a 16.48% jump to HK$5.23 on 20 Mar 2026 as the market closed. The 1875.HK stock move came on heavy volume of 13,704,000 shares, versus an average of 3,314,345. Traders cited sector momentum and company-specific interest in oncology pipelines. We break down the drivers, valuation, technicals and what Meyka AI’s model projects for the stock going forward.